Jessica Cohen

2 months ago | precisionmedicineonline.com | Jessica Cohen |Alison Kanski |Catherine Shaffer |Ciara Curtin

NEW YORK – The life sciences sector is still reeling from the announcement last week that the US National Institutes of Health intends to limit indirect costs for research grants to15 percent. The policy has those in the precision medicine space particularly worried about the effect this may have on the bourgeoning field's ability to continue to develop advanced treatments like cell and gene therapies and maintain an expert workforce.

Jan 15, 2025 | precisionmedicineonline.com | Jessica Cohen

NEW YORK – Biogen is "doubling down" on its drug development efforts in Alzheimer's disease, company President and CEO Christopher Viehbacher said Tuesday at the JP Morgan Healthcare Conference in San Francisco. Biogen in recent years has faced setbacks in this franchise as it struggled to market Aduhelm (aducanumab) amid a controversial approval and mixed efficacy data.

Jan 8, 2025 | precisionmedicineonline.com | Jessica Cohen

NEW YORK – A collaboration between cardiologists and genetic researchers across the US is collecting biological samples and other data from South Asian patients in the hopes of uncovering genetic factors associated with the high risk of cardiovascular disease in this population.

Dec 11, 2024 | precisionmedicineonline.com | Jessica Cohen

NEW YORK – Investigators at the American Society of Hematology's annual meeting in San Diego this week reported data on gene therapies for sickle cell disease and transfusion-dependent beta-thalassemia, two rare and inherited blood disorders. Below are brief reports on data readouts from the conference.

Dec 10, 2024 | precisionmedicineonline.com | Jessica Cohen

NEW YORK – Researchers from the University of California, Los Angeles, and University College London are advancing a gene therapy they say could be a cure for severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID). The researchers hope to seek the US Food and Drug Administration's approval to market the gene therapy.